Treatment with glimepiride, but not mitiglinide and short-acting insulin, resists body weight and abdominal fat reduction under dietary energy restriction

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 1, 2009, Pages 63-66

  Nakano, Takanari ^a,d,e   Inoue, Ikuo ^a   Satoh, Kentaro ^a   Yamazaki, Mochihito ^b   Awata, Takuya ^a   Kurihara, Susumu ^a   Goto, Sei Ichi ^c   Shinoda, Yu Ichi ^a   Komoda, Tsugikazu ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Kumagaya Surgical Hospital   (Japan)

^c MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Lifestyle intervention; Obesity; Oral hypoglycemic agents; Syndrome of inappropriate insulin secretion (SIIS); Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INNOLET; INSULIN; METFORMIN; MITIGLINIDE; PIOGLITAZONE; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ADULT; ARTICLE; BODY WEIGHT; CALORIC RESTRICTION; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT REDUCTION;

EID: 67549115724     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E587     Document Type: Article

References (13)

1. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med, 1988; 318:1231-1239
2. Carroll MF, Izard A, Riboni K, Burge MR, Schade DS: Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. Diabetes Care, 2002; 25:2147-2152
3. Krentz AJ, Bailey CJ: Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 2005; 65:385-411
4. Massi-Benedetti M: Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther, 2003; 25:799-816
5. Gottschalk M, Danne T, Vlajnic A, Cara JF: Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care, 2007; 30:790-794
6. Geisen K: Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung, 1988; 38:1120-1130
7. + channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol, 2001; 431:119-125
8. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K: Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther, 2007; 322:1-7
9. Ichikawa K, Yamato T, Ojima K, Tsuji A, Ishikawa K, Kusama H, Kojima M: Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol, 2002; 29:423-427
10. Ojima K, Ichikawa K, Fujimori Y, Aoyagi I, Yamato T, Tsuji A, Kusama H, Kojima M, Shibata N: Rapid onset-insulinotropic effect of mitiglinide calcium dihydrate (KAD-1229), a novel antipostprandial hyperglycemic agent. Jpn Pharmacol Ther, 2004; 32:73-80
11. Albu J, Raja-Khan N: The management of the obese diabetic patient. Prim Care, 2003; 30:465-491
12. Saito Y, Ishikawa Y, Shinomiya M, Shirai K, Yoshida S: Effects of protein-sparing modified fasting on obese Japanese patients. J Clin Biochem Nutr, 1987; 2:91-100
13. Saito Y, Shirai K, Oikawa S, Teramoto T, Yamada N, Ishibashi S, Tada N, Miyazaki S: Effectiveness of MicroDiet and ordinary meals on the improvement of glucose and lipid metabolism per unit weight reduction in obese diabetic patients. In 19th World Diabetes Congress Cape town, South Africa, 2006